Treatment for Keratoconus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mack Eye Center, Hoffman Estates, IL
Keratoconus+2 More
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether corneal collagen cross-linking is effective and safe for treating keratoconus.

See full description

Eligible Conditions

  • Keratoconus
  • Ectasia Corneal

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Keratoconus. Measurement will happen over the course of 3 and 6 months post-procedure.

Month 6
Decrease in maximum corneal curvature

Trial Safety

Trial Design

2 Treatment Groups

9 mW/cm2
1 of 2
18 mW/cm2
1 of 2
Active Control

This trial requires 100 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

9 mW/cm2CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
18 mW/cm2CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 and 6 months post-procedure
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 3 and 6 months post-procedure for reporting.

Closest Location

Mack Eye Center - Hoffman Estates, IL

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
The study participant is willing and able to comply with the schedule for follow-up visits. show original
The doctor asks the patient to remove their contact lenses prior to evaluation and treatment. show original
was associated with a decrease of ≥ 1.00 D in best-corrected visual acuity show original
with a stable cycloplegic refraction over a 6‐month period was used to define myopia show original
A central or inferior steepening on the Pentacam map suggests a posterior lens dislocation. show original
General Inclusion Criteria
If you are 18 years of age or older, you can vote in the election. show original
Signed written informed consent
Keratoconus is a progressive eye disease that affects the cornea show original
(K) from the previous examination was found in 9.00% of the study population show original

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

There is not cost involved in participating in this trial, so insurance won't be necessary.

See if you qualify for this trial
Get access to this novel treatment for Keratoconus by sharing your contact details with the study coordinator.